Susquehanna Fundamental Investments LLC bought a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 19,066 shares of the medical research company

Amgen stock is trading above $430 after a Q2 2026 earnings beat and higher full-year guidance sharpe

Amgen stock is holding above $430 after Q2 2026 results delivered a clear earnings and revenue beat

Amgen reported Phase 3 VESALIUS-CV data showing Repatha reduced death risk by 20% and lowered cardiovascular events in high-risk adults.

Amgen’s Phase 3 VESALIUS-CV data show Repatha cut death risk 20% in high-risk adults on statins—see ESC 2026 findings and key takeaways.

Sigma Planning Corp lessened its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 18.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 14,019 shares of the medical research company

Amgen has run roughly 51% in a year and now trades above the average Wall Street target, sitting near an all-time high after a Q2 beat-and-raise. The question buyers face is no longer whether the business works. It is whether anything is left at this price.

Amgen stock is holding above $430 as investors digest stronger-than-expected Q2 2026 results, double

Amgen stock is steady after second-quarter revenue of $10.05 billion and EPS of $6.29, with 2026 gui

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 12.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,390,910 shares of the medical

Van ECK Associates Corp lessened its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 2.5% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 188,288 shares of the medical research company

Benjamin Edwards Inc. elevó su posición en Amgen Inc. (NASDAQ:AMGN - Free Report) un 10,0% en el segundo trimestre, según su presentación más reciente ante la Comisión de Bolsa y Valores. El inversor institucional poseía 74.607 acciones de la empresa de investigación médica

Hennessy Advisors Inc. boosted its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 58.7% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 19,120 shares of the medical research company

Wellington Management Group LLP boosted its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 1,102.7% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,742,271 shares of the medical research company